ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
17.737,36
-0,64%
S&P 500
4.967,23
-0,88%
Dow Jones
37.986,40
0,56%
Euro vs US Dollar
1,06705
0,00%
Bitcoin
64.081,71
0,40%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Vanda Pharmaceuticals Inc (VNDA)

  7. Vanda Pharmaceuticals Inc (VNDA) News

VNDA Vanda Pharmaceuticals Inc

5,12
0,15 (3,02%)
20 Apr 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Vanda Pharmaceuticals Inc VNDA NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,15 3,02% 5,12 01:56:23
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
4,96 4,93 5,30 5,11 4,97
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
17.4.202416:21PRNUSVanda Pharmaceuticals Adopts Limited Duration Stockholder..
17.4.202415:02PRNUSVanda Pharmaceuticals Confirms Rejection of Unsolicited..
03.4.202416:25APSBiotech Catches Major Premarket Bid Following FDA Approval
03.4.202400:10PRNUSVanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S...
07.3.202422:31EDGAR2Form 8-K - Current report
06.3.202422:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202422:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202422:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202422:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202422:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.3.202413:00PRNUSVanda Pharmaceuticals Announces FDA Update for supplemental..
05.3.202403:14EDGAR2Form 144 - Report of proposed sale of securities
05.3.202403:12EDGAR2Form 144 - Report of proposed sale of securities
05.3.202403:10EDGAR2Form 144 - Report of proposed sale of securities
05.3.202403:08EDGAR2Form 144 - Report of proposed sale of securities
05.3.202403:06EDGAR2Form 144 - Report of proposed sale of securities
21.2.202422:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.2.202422:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.2.202422:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.2.202422:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.2.202422:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.2.202422:32EDGAR2Form 8-K - Current report
16.2.202422:31EDGAR2Form 8-K/A - Current report: [Amend]
08.2.202413:19EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
07.2.202422:07EDGAR2Form 8-K - Current report
07.2.202422:02PRNUSVanda Pharmaceuticals Reports Fourth Quarter and Full Year..
05.2.202422:34EDGAR2Form 8-K - Current report
05.2.202414:00PRNUSVanda Pharmaceuticals Announces FDA Update for supplemental..
31.1.202422:30PRNUSVanda Pharmaceuticals to Announce Fourth Quarter and Full..
31.1.202415:00PRNUSVanda Pharmaceuticals Receives FDA Approval to Proceed with..
30.1.202418:35PRNUSCourt Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag..
30.1.202401:00PRNUSCourt Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag..
26.1.202404:05PRNUSVanda Pharmaceuticals Announces a U.S. Patent Allowance for..
25.1.202419:07PRNUSVanda Pharmaceuticals announces the publication of an..
23.1.202417:52EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
23.1.202415:15PRNUSVanda Pharmaceuticals Receives FDA Approval to Proceed with..
19.1.202422:57DJNVanda Pharma's Trade Secrets Suit Against FDA Moves Forward
19.1.202421:56PRNUSFederal Court Allows Vanda Pharmaceuticals' Lawsuit to..
17.1.202421:46PRNUSVanda Pharmaceuticals announces the publication of Efficacy..
12.1.202418:21PRNUSVanda Pharmaceuticals Comments on FDA's Recently Announced..
04.1.202422:30PRNUSVanda Pharmaceuticals Announces Participation in the J.P...
15.12.202322:15EDGAR2Form 8-K - Current report
07.12.202323:19EDGAR2Form 8-K - Current report
07.12.202313:00PRNUSVanda Pharmaceuticals Acquires U.S. and Canadian Rights to..
05.12.202312:23DJNVanda Pharmaceuticals Shares Rise Premarket on FDA Review of..
05.12.202300:45DJNVanda Pharma Says FDA Accepts New Drug Application for..
05.12.202300:00PRNUSVanda Pharmaceuticals Announces that U.S. Food and Drug..
09.11.202322:30PRNUSVanda Pharmaceuticals Announces Participation at November..
09.11.202313:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.11.202322:05EDGAR2Form 8-K - Current report

Kürzlich von Ihnen besucht

NASDAQ
VNDA
Vanda Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten